Annual Drug Patent Expirations for RETEVMO
Retevmo is a drug marketed by Loxo Oncology Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.
This drug has thirty-four patent family members in twenty-four countries.
The generic ingredient in RETEVMO is selpercatinib. One supplier is listed for this compound. Additional details are available on the selpercatinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
